top of page

Biopharma Execs Weigh Controversial Move: Opting Out of Medicare to Escape Drug Price Negotiations

A panel hosted last week by JP Morgan and the industry group PhRMA further hinted at possible sweeping changes to the U.S. drug development landscape brought on by the Inflation Reduction Act’s Drug Price Negotiation Program. Specifically, biopharma execs suggested that companies may choose to opt out of Medicare coverage for their drugs to avoid having to negotiate pricing...


bottom of page